Skip to main content

Absci

Absci Corp is an American generative AI drug creation company deploying artificial intelligence and synthetic biology for biologic drug discovery. The company utilizes its Integrated Drug Creation platform to design and engineer novel antibodies and protein therapeutics in silico. Principal revenues are generated through upfront licensing fees, R&D milestone payments, and future royalty sharing with biopharmaceutical partners. Core end markets serve global pharmaceutical corporations, biotechnology developers, and academic research institutions. Absci holds a prominent pioneer position in the biopharmaceutical industry as a technology developer integrating generative AI models with high-throughput wet-lab antibody screening. The company is headquartered in Vancouver, Washington, and its common stock trades on the Nasdaq Global Select Market.

2 of the funds FundTelligence covers report a position in Absci.

Legal name
ABSCI CORP
Sector
Health Care
Country
United States
Funds holding it
2
Exposure themes
Artificial Intelligence, Drug Discovery & Design, Healthcare

Funds holding Absci

Loading...